Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the Treatment of Myeloproliferative Neoplasms— Implications for a JAK2 Inhibitor Era
Oncology & Hematology Review (US)
doi 10.17925/ohr.2011.07.1.61
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2011
Authors
Publisher
Touch Medical Media, Ltd.